See more : Daido Signal Co., Ltd. (6743.T) Income Statement Analysis – Financial Results
Complete financial analysis of Hansa Biopharma AB (publ) (HNSBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hansa Biopharma AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Keskisuomalainen Oyj (KSLAV.HE) Income Statement Analysis – Financial Results
- Starcom plc (STAR.L) Income Statement Analysis – Financial Results
- China Jicheng Holdings Limited (1027.HK) Income Statement Analysis – Financial Results
- Microlise Group plc (SAAS.L) Income Statement Analysis – Financial Results
- Danakali Limited (DNK.AX) Income Statement Analysis – Financial Results
Hansa Biopharma AB (publ) (HNSBF)
About Hansa Biopharma AB (publ)
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 134.09M | 154.53M | 33.88M | 6.10M | 3.36M | 3.36M | 3.44M | 2.58M | 5.43M | 4.72M | 1.73M | 2.62M | 1.28M | 4.45M | 2.98M | 103.68K |
| Cost of Revenue | 63.14M | 38.48M | 15.43M | 997.00K | 866.00K | 916.00K | 221.00K | 217.00K | 658.00K | 245.00K | 317.96K | -2.49M | 1.71M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 70.95M | 116.05M | 18.45M | 5.10M | 2.50M | 2.44M | 3.22M | 2.36M | 4.78M | 4.47M | 1.41M | 5.11M | -432.44K | 4.45M | 2.98M | 103.68K |
| Gross Profit Ratio | 52.91% | 75.10% | 54.47% | 83.65% | 74.26% | 72.72% | 93.58% | 91.59% | 87.89% | 94.80% | 81.59% | 194.96% | -33.73% | 100.00% | 100.00% | 100.00% |
| Research & Development | 411.33M | 346.24M | 230.76M | 227.19M | 192.95M | 154.56M | 137.06M | 82.85M | 44.26M | 21.74M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 450.49M | 337.86M | 327.27M | 202.99M | 167.31M | 90.39M | 43.72M | 29.70M | 28.24M | 17.42M | 11.26M | 14.14M | 21.16M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 450.49M | 337.86M | 327.27M | 202.99M | 167.31M | 90.39M | 43.72M | 29.70M | 28.24M | 17.42M | 11.26M | 14.14M | 21.16M | 0.00 | 0.00 | 0.00 |
| Other Expenses | -2.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 859.45M | 692.17M | 558.03M | 430.18M | 360.09M | 244.22M | 179.34M | 113.50M | 70.98M | 29.18M | 19.05M | 21.91M | 27.46M | 24.44M | 18.72M | 16.01M |
| Cost & Expenses | 922.59M | 730.65M | 573.46M | 431.18M | 360.96M | 245.14M | 179.56M | 113.71M | 71.64M | 29.43M | 19.37M | 19.43M | 29.18M | 24.44M | 18.72M | 16.01M |
| Interest Income | 27.99M | 8.83M | 67.00K | 388.00K | 118.00K | 52.00K | 97.00K | 23.00K | 0.00 | 42.00K | 93.22K | 346.44K | 47.78K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 105.52M | 43.67M | 694.00K | 257.00K | 466.00K | 706.00K | 695.00K | 103.00K | 65.00K | 123.00K | 15.76K | 4.74K | 155.41K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 19.79M | 12.05M | 8.61M | 7.55M | 6.91M | 1.84M | 3.78M | 3.45M | 989.00K | 1.35M | 96.65K | 126.79K | -52.36M | 0.00 | 381.77K | 415.40K |
| EBITDA | -705.50M | -554.26M | -538.83M | -414.75M | -351.66M | -245.47M | -172.23M | -107.60M | -65.21M | -24.48M | -17.45M | -16.27M | -24.29M | -19.99M | -15.36M | -15.47M |
| EBITDA Ratio | -526.12% | -355.47% | -1,588.95% | -6,801.44% | -10,466.94% | -7,284.69% | -5,004.68% | -4,174.49% | -1,200.07% | -494.44% | -1,010.39% | -623.73% | -2,175.42% | -449.46% | -514.75% | -14,925.86% |
| Operating Income | -788.50M | -588.59M | -546.98M | -422.81M | -359.67M | -246.50M | -176.08M | -111.14M | -66.20M | -24.71M | -17.64M | -16.81M | 24.46M | -19.99M | -15.74M | -15.91M |
| Operating Income Ratio | -588.02% | -380.90% | -1,614.55% | -6,933.54% | -10,691.68% | -7,340.62% | -5,115.72% | -4,309.23% | -1,218.27% | -523.94% | -1,021.38% | -641.80% | 1,907.97% | -449.46% | -527.54% | -15,341.72% |
| Total Other Income/Expenses | -42.32M | -33.86M | -1.15M | 1.91M | -2.00M | -6.24M | -616.00K | -17.00K | -65.00K | -4.33M | 67.00K | 331.97K | -107.63K | -150.48K | -71.60K | 16.52M |
| Income Before Tax | -830.81M | -609.98M | -548.13M | -420.89M | -359.59M | -248.01M | -176.70M | -111.15M | -66.27M | -29.04M | -17.56M | -16.47M | -24.57M | -20.14M | -15.81M | 616.70K |
| Income Before Tax Ratio | -619.57% | -394.74% | -1,617.95% | -6,902.15% | -10,689.42% | -7,385.77% | -5,133.61% | -4,309.89% | -1,219.47% | -615.82% | -1,016.90% | -628.75% | -1,916.36% | -452.84% | -529.94% | 594.83% |
| Income Tax Expense | 908.00K | 1.16M | 152.00K | -40.00K | 417.00K | -40.00K | -39.00K | -23.00K | 0.00 | 42.00K | 93.22K | 346.44K | 65.00 | -1.30M | 0.00 | 3.17M |
| Net Income | -831.72M | -611.13M | -548.28M | -420.85M | -360.01M | -247.97M | -176.66M | -111.13M | -66.27M | -29.04M | -17.56M | -16.47M | -24.57M | -18.84M | -15.81M | -2.56M |
| Net Income Ratio | -620.25% | -395.49% | -1,618.40% | -6,901.49% | -10,701.81% | -7,384.57% | -5,132.48% | -4,309.00% | -1,219.47% | -615.82% | -1,016.90% | -628.75% | -1,916.37% | -423.62% | -529.94% | -2,467.50% |
| EPS | -15.83 | -13.60 | -12.33 | -9.98 | -9.00 | -6.47 | -4.97 | -3.37 | -2.12 | -1.09 | -0.72 | -0.71 | -2.11 | -2.27 | -3.12 | -0.51 |
| EPS Diluted | -15.83 | -13.60 | -12.33 | -9.98 | -9.00 | -6.47 | -4.96 | -3.37 | -2.12 | -1.09 | -0.72 | -0.71 | -2.11 | -2.27 | -3.12 | -0.51 |
| Weighted Avg Shares Out | 52.54M | 44.92M | 44.47M | 42.18M | 40.02M | 38.33M | 35.52M | 33.01M | 31.21M | 26.54M | 24.54M | 23.24M | 11.64M | 8.31M | 5.06M | 5.00M |
| Weighted Avg Shares Out (Dil) | 52.54M | 44.92M | 44.47M | 42.18M | 40.02M | 38.33M | 35.61M | 33.01M | 31.21M | 26.54M | 24.54M | 23.24M | 11.64M | 8.31M | 5.06M | 5.00M |
Genethon and Hansa Biopharma Announce Initiation of a Phase 2 Trial of imlifidase as a Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome
LUND, Sweden & EVRY, France--(BUSINESS WIRE)--This is a crucial step in order to make gene therapy more effective and to increase the number of patients able to access it.
Hansa Biopharma AB (publ) (HNSBF) Q3 2024 Results Conference Call Transcript
Start Time: 08:00 January 1, 0000 8:55 AM ET Hansa Biopharma AB (publ) (OTC:HNSBF) Q3 2024 Results Conference Call October 17, 2024, 08:00 AM ET Company Participants Søren Tulstrup - President and CEO Evan Ballantyne - CFO Hitto Kaufmann -...
Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results
Q3 2024 marks highest ever in-market quarterly sales performance and fourth consecutive quarter of strong sales performance LUND, Sweden , Oct. 17, 2024 /PRNewswire/ -- Hansa Biopharma today announced its interim report for January-September and third quarter 2024 financial results....
Hansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
LUND, Sweden , Sept. 5, 2024 /PRNewswire/ -- Hansa Biopharma today announced that Søren Tulstrup will participate in a Fireside chat hosted by Douglas Tsao, Managing Director and Senior Financial Analyst at H.C.
Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis
LUND, Sweden , Aug. 23, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (Nasdaq Stockholm: HNSA), today announced that Matthew Shaulis, Chief Commercial Officer and US President has decided to leave the company in late September. Effective immediately,...
Hansa Biopharma AB (publ) (HNSBF) Q2 2024 Earnings Call Transcript
Hansa Biopharma AB (publ) (OTCPK:HNSBF) Q2 2024 Results Conference Call July 18, 2024 8:00 AM ET Company Participants Søren Tulstrup - Chief Executive Officer Matt Shaulis - Chief Commercial Officer and U.S. President Hitto Kaufmann - Chief Scientific Officer Evan...
Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business Update
LUND, Sweden , July 18, 2024 /PRNewswire/ -- Hansa Biopharma today announced its first half and second quarter 2024 financial results and business update. Søren Tulstrup, President and CEO, Hansa Biopharma said: "For the third consecutive quarter, Hansa Biopharma delivered...
Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial
LUND, Sweden , May 31, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ Stockholm: HNSA), today announced recruitment and randomization in its US ConfIdeS trial is complete. ConfIdeS is a pivotal Phase 3 open label, randomized, controlled trial...
Hansa Biopharma: increase in number of shares and votes
LUND, Sweden , May 3, 2024 /PRNewswire/ -- Hansa Biopharma AB (publ), ("Hansa" or the "Company") (STO: HNSA) today announced that the company's registered share capital and number of shares and votes have increased through the issue of 10,474,740 new...
Hansa Biopharma AB (publ) (HNSBF) Q1 2024 Earnings Call Transcript
Hansa Biopharma AB (publ). (OTCQX:HCHDF) Q1 2024 Earnings Conference Call April 18, 2024 8:00 AM ET Company Participants Søren Tulstrup - Chief Executive Officer Matt Shaulis - Chief Commercial Officer and U.S. President Hitto Kaufmann - Chief Scientific Officer Evan...
Source: https://incomestatements.info
Category: Stock Reports